Related Experiment Videos

Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells

J L Wang1, D Liu, Z J Zhang

  • 1Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Insights

A novel small molecule, HA14-1, targets the Bcl-2 protein to induce apoptosis in cancer cells. This discovery offers a new chemical probe for studying programmed cell death and developing cancer therapeutics.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Bcl-2 proteins regulate apoptosis, a process crucial in diseases like cancer.
  • Previous research demonstrated that Bcl-2 binding peptides could induce apoptosis in leukemia cells.

Purpose of the Study:

  • To discover a small molecule inhibitor of Bcl-2.
  • To investigate the mechanism of action of the novel compound HA14-1.
  • To evaluate HA14-1 as a potential therapeutic agent for cancer.

Main Methods:

  • Structure-based computer screening to identify Bcl-2 ligands.
  • In vitro binding assays to confirm interaction with Bcl-2.
  • Apoptosis induction studies in human acute myeloid leukemia cells (HL-60) and mouse embryonic fibroblast cells (Apaf-1(+/+) and Apaf-1(-/-)).
  • Assessment of mitochondrial membrane potential and caspase activation (caspase-9 and caspase-3).

Main Results:

  • HA14-1, a nonpeptidic small molecule, was identified as a Bcl-2 ligand.
  • HA14-1 induced apoptosis in Bcl-2-overexpressing leukemia cells, involving mitochondrial pathway activation.
  • Apoptosis induction by HA14-1 was dependent on Apaf-1.
  • HA14-1 did not inhibit Fas-mediated apoptosis.

Conclusions:

  • HA14-1 functions as a Bcl-2 inhibitor, triggering apoptosis through Apaf-1 and caspase activation.
  • This small molecule serves as a valuable chemical probe for in vivo studies of Bcl-2-regulated apoptosis.
  • HA14-1 holds potential for the development of novel anti-cancer therapeutics.

Related Concept Videos